Convalescent Plasma to Treat COVID-19: A Two-Center, Randomized, Double-Blind Clinical Trial

被引：4

作者：

Ventura-Enriquez, Yanet ^{[1
]}

Cabello-Gutierrez, Carlos ^{[2
]}

Augusto Perez-Calatayud, Angel ^{[3
]}

Cortina-De la Rosa, Evelyn ^{[1
,4
]}

Javier Fareli-Gonzalez, Christian ^{[5
]}

Castillo-Juarez, Paola ^{[2
,6
]}

Pena-Perez Carlos, Alberto ^{[7
]}

Omar Zavaleta-Martinez, Eli ^{[7
]}

Diaz-Padilla, Elizabeth ^{[1
,8
]}

Murrieta, Sandra ^{[1
]}

Deyanira Alvarez-Jimenez, Violeta ^{[9
]}

Diaz Ponce-Medrano, Juan Alberto ^{[10
]}

Casillas-Suarez, Catalina ^{[3
]}

Angelica Ocampo-Ocampo, Maria ^{[3
]}

Vargas-De-Leon, Cruz ^{[11
,12
]}

Fernandez-Sanchez, Veronica ^{[1
,11
,13
]}

机构：

[1] Ctr Med Naval CEMENAV, Banco Sangre, Ciudad De Mexico 04470, Mexico

[2] Inst Nacl Enfermedades Resp INER, Dept Invest Virol & Micol, Ciudad De Mexico 14080, Mexico

[3] Hosp Gen Mexico Dr Eduardo Liceaga, Div Med Crit, Ciudad De Mexico 06720, Mexico

[4] Inst Nacl Cardiol Ignacio Chavez, Dept Hematol, Ciudad De Mexico 14080, Mexico

[5] Natl Ctr Technol Excellence Hlth, Guias Pract Clin, Ciudad De Mexico 06600, Mexico

[6] Inst Politecn Nacl IPN, Dept Microbiol, Escuela Nacl Ciencias Biol, Ciudad De Mexico 11340, Mexico

[7] Ctr Med Naval CEMENAV, Unidad Cuidados Intensivos, Ciudad De Mexico 04470, Mexico

[8] UNAM, Fac Quim, Ciudad De Mexico 04510, Mexico

[9] Ctr Med Naval CEMENAV, Biol Mol & BSL 3, Ciudad De Mexico 04470, Mexico

[10] Ctr Med Naval CEMENAV, Direcc Gen, Ciudad De Mexico 04470, Mexico

[11] Hosp Juarez Mexico, Div Invest, Ciudad De Mexico 07760, Mexico

[12] Inst Politecn Nacl IPN, Escuela Super Med, Secc Estudios Invest & Posgrad, Ciudad De Mexico 11340, Mexico

[13] Univ Nacl Autonoma Mexico, Fac Estudios Super Iztacala FES Iztacala, Ciudad De Mexico 54090, Mexico

来源：

LIFE-BASEL | 2022年 / 12卷 / 11期

关键词：

convalescent plasma treatment; COVID-19; neutralizing antibodies; SARS-CoV-2; MORTALITY;

D O I：

10.3390/life12111767

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Background: The use of convalescent plasma (CP) has been considered for its immunological mechanisms that could benefit patients in moderate and severe stages of COVID-19. This study evaluated the safety and efficacy of the use of donor CP for COVID-19. Material and methods: A double-blind, randomized controlled clinical trial was conducted from May to October 2020. Thirty-nine participants with moderate (II) and severe (III) stages of COVID-19 confirmed by RT-PCR were included. The study randomization rate was set at 3:1. CPs were chosen for application with a neutralizing antibody titer of >= 1:32. Results: We observed a significantly lower 21-day post-transfusion mortality HR: 0.17 (95.0% CI [0.07-0.45, p < 0.001]) in the group receiving CP compared with the control group; protective units (PU) in the group receiving convalescent plasma after seven days were significantly higher (512 (32-16,384) vs. 96 (32-256), p = 0.01); the PAO(2)/FIO2 index showed a significant improvement in the group receiving CP (251.01 (109.4) vs. 109.2 (62.4), p < 0.001, in the control group). Conclusion: CP is safe and effective, as it decreased mortality in the CP group compared with the control group.

引用

页数：13

共 27 条

[1] Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study
Abolghasemi, Hassan
Eshghi, Peyman
Cheraghali, Abdol Majid
Fooladi, Abbas Ali Imani
Moghaddam, Farzaneh Bolouki
Imanizadeh, Sina
Maleki, Matin Moeini
Ranjkesh, Mohammad
Rezapour, Mohammad
Bahramifar, Ali
Einollahi, Behzad
Hosseini, Mohammad Javad
Jafari, Nematollah Joneidi
Nikpouraghdam, Mohamad
Sadri, Nariman
Tazik, Mokhtar
Sali, Shanaz
Okati, Shamsi
Askari, Elham
Tabarsi, Payam
Aslani, Jafar
Sharifipour, Ehsan
Jarahzadeh, Mohammad Hossein
Khodakarim, Nastaran
Salesi, Mahmood
Jafari, Ramezan
Shahverdi, Samira
[J]. TRANSFUSION AND APHERESIS SCIENCE, 2020, 59 (05)
[2] Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Agarwal, Anup
Mukherjee, Aparna
Kumar, Gunjan
Chatterjee, Pranab
Bhatnagar, Tarun
Malhotra, Pankaj
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2020, 371
[3] [Anonymous], 2021, RECOVERY STATEMENT
[4] [Anonymous], CONCOR 1 RANDOMIZED
[5] [Anonymous], 2021, REMAP CAP STATEMENT
[6] Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol
Arabi, Yaseen
Balkhy, Hanan
Hajeer, Ali H.
Bouchama, Abderrezak
Hayden, Frederick G.
Al-Omari, Awad
Al-Hameed, Fahad M.
Taha, Yusri
Shindo, Nahoko
Whitehead, John
Merson, Laura
AlJohani, Sameera
Al-Khairy, Khalid
Carson, Gail
Luke, Thomas C.
Hensley, Lisa
Al-Dawood, Abdulaziz
Al-Qahtani, Saad
Modjarrad, Kayvon
Sadat, Musharaf
Rohde, Gernot
Leport, Catherine
Fowler, Robert
[J]. SPRINGERPLUS, 2015, 4 : 1 - 8
[7] Avendano-Sola C., 2020, medRxiv, DOI DOI 10.1101/2020.08.26.20182444
[8] Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
[9] Food and Drug Administration, COVID 19 CONV PLASM
[10] Huang CL, 2020, LANCET, V395, P497, DOI [10.1016/S0140-6736(20)30183-5, 10.1016/S0140-6736(20)30211-7]

← 1 2 3 →